Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 6/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.42 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.42 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.42 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL63468 | 0.78 | ALDH1A1 (0.67) | KIF11ALDH1A1TSHRCES2CES1 | |
| SCHEMBL4471260 | 0.77 | ALDH1A1 (0.50) | KIF11ALDH1A1TSHRCES2CES1 | |
| SCHEMBL10672363 | 0.77 | ALDH1A1 (0.50) | KIF11ALDH1A1TSHRCES2CES1 | |
| SCHEMBL1508480 | 0.77 | ALDH1A1 (0.50) | KIF11ALDH1A1TSHRCES2CES1 | |
| SCHEMBL11598948 | 0.77 | ALDH1A1 (0.50) | KIF11ALDH1A1TSHRCES2CES1 | |
| SCHEMBL1539075 | 0.77 | TSHR (0.50) | KIF11ALDH1A1TSHRCES2CES1 | |
| SCHEMBL7641117 | 0.72 | ALDH1A1 (0.46) | KIF11ALDH1A1TSHRCES2CES1 | |
| SCHEMBL21566844 | 0.72 | ALDH1A1 (0.46) | KIF11ALDH1A1TSHRCES2CES1 | |
| SCHEMBL677928 | 0.72 | ALDH1A1 (0.46) | KIF11ALDH1A1TSHRCES2CES1 | |
| Iodide SCHEMBL29093539 | 0.72 | ALDH1A1 (0.59) | KIF11ALDH1A1TSHRCES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7067538-B2 | MCP-1 receptor antagonists and methods of use thereof | WARNER-LAMBERT COMPANY, LLC (US) | 2006-06-27 | — | — | US | disclosed |
| US-20050171163-A1 | MCP-1 receptor antagonists and methods of use thereof | BRATTON LARRY D (US) | 2005-08-04 | — | — | US | disclosed |
| EP-1539685-A1 | MCP-1 RECEPTOR ANTAGONISTS AND METHOD OF USE THEREOF | Warner-Lambert Company LLC (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004014847-A1 | MCP-1 RECEPTOR ANTAGONISTS AND METHOD OF USE THEREOF | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171163-A1 | MCP-1 receptor antagonists and methods of use thereof | CCR2, CCR1, CCL2 | KIF11 3752/4885ALDH1A1 565/4885TSHR 744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.